Zydus Cadila launches ‘Ujvira’ to treat breast cancer
May 24, 2021
Treatment cost to come down by 80% for the patients
In a breakthrough in breast cancer treatment, pharma major Zydus Cadila (Cadila Healthcare Limited) on Monday announced the launch of Trastuzumab Emtansine, the first Antibody Drug Conjugate (ADC) biosimilar, which is considered a highly effective drug for treating both early and advanced HER2-positive breast cancer. The company launched the product under the brand name ‘Ujvira’.
The human epidermal growth factor receptor 2 (HER2)-positive breast cancer is considered an aggressive form and constitutes 20 to 25% of all breast cancers, the company informed, adding that its new product can reduce the treatment cost by almost 80 per cent.